Stock GETI B GETINGE AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Getinge AB

Equities

GETI B

SE0000202624

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:59 2024-04-26 am EDT 		5-day change 1st Jan Change
235.1 SEK +2.57% Intraday chart for Getinge AB +10.48% +4.81%
Apr. 24 GETINGE : Q1 24: Investors look beyond the top-line miss Alphavalue
Apr. 22 Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest DJ

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 47,392 52,322 107,613 58,914 61,092 64,034 - -
Enterprise Value (EV) 1 56,158 56,472 111,222 61,516 69,104 70,408 68,332 65,775
P/E ratio 38.8 x 16.2 x 36.2 x 23.6 x 25.3 x 23 x 19.7 x 17.4 x
Yield 0.86% 1.56% 1.01% 1.96% 1.96% 2.04% 2.26% 2.54%
Capitalization / Revenue 1.78 x 1.75 x 3.98 x 2.08 x 1.92 x 1.87 x 1.79 x 1.71 x
EV / Revenue 2.11 x 1.89 x 4.11 x 2.17 x 2.17 x 2.06 x 1.91 x 1.75 x
EV / EBITDA 11.3 x 7.54 x 16.5 x 10.4 x 12.4 x 10.8 x 9.37 x 8.27 x
EV / FCF 21.5 x 9.18 x 19.8 x 32.4 x 43.1 x 21.4 x 18.3 x 15.7 x
FCF Yield 4.65% 10.9% 5.06% 3.08% 2.32% 4.67% 5.45% 6.37%
Price to Book 2.26 x 2.44 x 4.27 x 1.93 x 2.01 x 1.97 x 1.85 x 1.72 x
Nbr of stocks (in thousands) 272,370 272,370 272,370 272,370 272,370 272,370 - -
Reference price 2 174.0 192.1 395.1 216.3 224.3 235.1 235.1 235.1
Announcement Date 1/30/20 1/28/21 1/28/22 2/1/23 2/1/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 26,559 29,819 27,049 28,292 31,827 34,194 35,849 37,542
EBITDA 1 4,986 7,487 6,754 5,891 5,574 6,526 7,291 7,952
EBIT 1 2,813 5,261 4,939 4,096 3,653 4,418 5,070 5,655
Operating Margin 10.59% 17.64% 18.26% 14.48% 11.48% 12.92% 14.14% 15.06%
Earnings before Tax (EBT) 1 1,909 4,485 4,188 3,472 3,343 3,933 4,626 5,257
Net income 1 1,222 3,239 2,970 2,491 2,412 2,819 3,266 3,706
Net margin 4.6% 10.86% 10.98% 8.8% 7.58% 8.25% 9.11% 9.87%
EPS 2 4.480 11.89 10.90 9.150 8.860 10.21 11.91 13.51
Free Cash Flow 1 2,612 6,154 5,630 1,897 1,604 3,286 3,724 4,190
FCF margin 9.83% 20.64% 20.81% 6.71% 5.04% 9.61% 10.39% 11.16%
FCF Conversion (EBITDA) 52.39% 82.2% 83.36% 32.2% 28.78% 50.35% 51.08% 52.7%
FCF Conversion (Net income) 213.75% 190% 189.56% 76.15% 66.5% 116.55% 114.03% 113.06%
Dividend per Share 2 1.500 3.000 4.000 4.250 4.400 4.800 5.313 5.977
Announcement Date 1/30/20 1/28/21 1/28/22 2/1/23 2/1/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 7,987 6,182 6,670 6,941 8,498 7,141 7,176 7,607 9,903 7,513 7,921 8,337 10,454 7,862 8,166
EBITDA 1 2,118 1,235 1,350 1,579 1,727 1,380 902 1,525 1,766 1,255 1,351 1,651 2,315 1,473 1,524
EBIT 1 1,652 797 913 1,121 1,265 921 442 1,047 1,243 784 877.8 1,169 1,828 973 1,024
Operating Margin 20.68% 12.89% 13.69% 16.15% 14.89% 12.9% 6.16% 13.76% 12.55% 10.44% 11.08% 14.03% 17.49% 12.38% 12.54%
Earnings before Tax (EBT) 1 1,075 749 867 1,075 781 826 305 1,227 986 638 704.2 939.3 1,626 853 904
Net income 1 771 534 603 798 556 586 214 894 718 459 520.7 700.7 1,139 - -
Net margin 9.65% 8.64% 9.04% 11.5% 6.54% 8.21% 2.98% 11.75% 7.25% 6.11% 6.57% 8.4% 10.9% - -
EPS 2 2.830 1.960 2.210 2.930 2.040 2.150 0.7900 3.280 2.640 1.690 1.919 2.573 4.182 - -
Dividend per Share 4.000 - - - - - - - - - - - - - -
Announcement Date 1/28/22 4/26/22 7/19/22 10/19/22 2/1/23 4/26/23 7/18/23 10/23/23 2/1/24 4/22/24 - - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 8,766 4,150 3,609 2,602 8,012 6,374 4,298 1,741
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.758 x 0.5543 x 0.5344 x 0.4417 x 1.437 x 0.9768 x 0.5895 x 0.2189 x
Free Cash Flow 1 2,612 6,154 5,630 1,897 1,604 3,286 3,724 4,190
ROE (net income / shareholders' equity) 6.2% 15.1% 12.9% 8.9% 7.8% 9.27% 10% 10.7%
ROA (Net income/ Total Assets) 2.77% 7.22% 6.63% 5.16% 4.74% 5.07% 5.75% 6.27%
Assets 1 44,116 44,863 44,785 48,294 50,889 55,654 56,805 59,074
Book Value Per Share 2 77.00 78.90 92.40 112.0 112.0 119.0 127.0 136.0
Cash Flow per Share 2 14.10 26.40 24.10 - 10.90 21.60 18.00 19.60
Capex 1 1,220 1,045 930 1,136 1,353 1,434 1,493 1,554
Capex / Sales 4.59% 3.5% 3.44% 4.02% 4.25% 4.2% 4.16% 4.14%
Announcement Date 1/30/20 1/28/21 1/28/22 2/1/23 2/1/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Getinge AB

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
235.1 SEK
Average target price
235.5 SEK
Spread / Average Target
+0.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

1st Jan change Capi.
GETINGE AB Stock Getinge AB
+4.81% 5.84B
SHOCKWAVE MEDICAL, INC. Stock Shockwave Medical, Inc.
+73.17% 12.38B
PENUMBRA, INC. Stock Penumbra, Inc.
-18.74% 7.92B
MASIMO CORPORATION Stock Masimo Corporation
+16.15% 7.2B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+5.99% 5.01B
APT MEDICAL INC. Stock APT Medical Inc.
+27.07% 4.53B
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-21.67% 3.88B
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-40.82% 2.23B
SKAN GROUP AG Stock SKAN Group AG
+1.49% 2.02B
SHENZHEN YHLO BIOTECH CO., LTD. Stock Shenzhen YHLO Biotech Co., Ltd.
+5.07% 1.88B
Medical Equipment
  1. Stock Market
  2. Equities
  3. GETI B Stock
  4. Financials Getinge AB